Key result
Recombinant human soluble thrombomodulin administration was significantly associated with reduced in-hospital mortality in high-risk patients with sepsis-induced DIC (APACHE II 24-29) (HR 0.281).
Why the study?
Does recombinant human soluble thrombomodulin reduce in-hospital mortality in patients with sepsis-induced DIC requiring ventilator management?
Population
162 patients with sepsis-induced disseminated intravascular coagulation who required ventilator management
Comparison
Recombinant human soluble thrombomodulin (rhTM) vs No rhTM
Design
Cohort
Follow-up
in-hospital
Authors
Loading...
May support rhTM in high-risk sepsis DIC; leaves open confirmation by RCTs before practice change.
Cohort (n=162)
Yes
Does recombinant human soluble thrombomodulin reduce in-hospital mortality in patients with sepsis-induced DIC requiring ventilator management?
Hazard Ratio: 0.281 (95% CI 0.093–0.85)
p-value: p=0.025
Recombinant human soluble thrombomodulin may provide a survival benefit in patients with sepsis-induced DIC who have a high baseline risk of death (APACHE II 24-29 or SOFA ≥11).
Yoshimura et al. (2015) conducted a cohort in Sepsis-induced disseminated intravascular coagulation (DIC) (n=162). Recombinant human soluble thrombomodulin (rhTM) vs. No rhTM was evaluated on In-hospital mortality in high-risk patients (APACHE II: 24 to 29) (HR 0.281, 95% CI 0.093 to 0.850, p=0.025). Recombinant human soluble thrombomodulin administration was significantly associated with reduced in-hospital mortality in high-risk patients with sepsis-induced DIC (APACHE II 24-29) (HR 0.281).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: